Orally administered immunomodulatory drugs have recently demonstrated the ability to induce an oral tolerance via inhibition of effector T cells and induction of certain subsets ofregulatory T cells (Tregs)
which have the potential to prevent several autoimmune diseases. In the present study, we hypothesized that short-term, low-dose, oral FTY720 administration may induce latency-associated peptide (LAP) Tregs and CD4+Foxp3+Tregs in atherogenesis, potentially resulting in remission of early development of atherosclerosis in apolipoprotein E-deficient(APO.E-1 -) mice. FTY720 was orally administered to APOE-I-mice 4 weeks of age on a high-cholesterol diet and atheresclerosls was, assessed at 8 weeks of age. Oral administration of FTY720 significantly reduced atherosclerotic lesion formation compared with control mice. We observed a significant increase in LAP+and Foxp3+cells in the CD4+T-cell population of FTY720-treated mice in association with increased production of the anti-inflammatory cytokine transforming growth factor-B (TGF-P) as well as suppressed T-helper type 1 immune responses. Our findings reveal that short-term, low-dose oral FTY720 treatment had great benefits in inhibiting early development of atherosclerosis in mice via induction of a regulatory T-cell response and inhibition of effector T responses. These findings suggest that oral immune modulation may. represent an attractive therapeutic approach to atherosclerosis.
As a chronic inflammatory autoimmune disease (l, 2), the development of atherosclerosis may be related to defects in immunologic tolerance, therefore strategies to induce immune tolerance are being developed for the treatment of atherosclerosis. One such effective approach involves administering an external agent via a natural route which could be of unique immunologic importance as it may stimulate a continuous natural immunologic event. This approach has been proposed to induce peripheral tolerance via two primary mechanisms: low doses of agents favor the generation of regulatory cell-driven tolerance whereas high doses of agents favor either clonal deletion or anergy of CD4+T-cells of effector T cells(3). FTY720, a synthetic structural analogue of sphingosine isolated from culture filtrates of the ascomycete Isaria sinclairii and related to the drug Myriocin, may be a representative of both the abovementioned mechanisms. FTY720 has been implicated in long-term remission of some autoimmune diseases, supporting a role as a primary agent for use in suppressing transplant rejection and graft-versus-host disease (4) . Oral FTY720 administration may induce tolerance via modulation ofdendritic cell differentiation and migration in animal models and may be able to produce lymphopenia by sequestering lymphocytes from blood into lymph organs, thereby preventing their recruitment into sites of inflammation (5, 6) . Based on these findings, several studies have been carried out with results supporting protective effects of FTY720 on atherosclerosis in the low-density lipoprotein (LDL) r/-andAPOE-/-mouse models (7, 8) .
In addition, FTY720 has recently been studied to elucidate its effect on Tregs (9) . Accumulating data suggests that FTY720 may be beneficial in alleviating symptoms of some autoimmune diseases via direct effects on the number of Tregs and their functional activity (10, 11) . Recent studies have demonstrated successful inhibition ofatherosclerosis via induction of several subsets of Tregs, such as CD4 + LAP + Tregs andCD4 + Foxp3 "(Forkhead box P3) Tregs (12) , through the maintenance of immunologic unresponsiveness to self-antigens (13) and down-regulation of activated T-cell responses resulting in inhibition of atherosclerosis initiation and development (14) .
However, there is no current evidence demonstrating that FTY720 inhibits the development ofatherosclerosis via the induction ofTregs. Therefore, we hypothesized that induction of CD4 +LAP+ Tregs and CD4 + Foxp3 +Tregs via oral FTY720 treatment would inhibit atherosclerosis in ApoE "mice. Our findings provide initial evidence suggesting that oral FTY720 treatment induces CD4 + LAP + Tregs and CD4 + Foxp3 + Tregs which suppress pathogenic immune processes pivotal for atherogenesis through a TGF-l3-dependent way and consequently inhibit the early development of atherosclerosis.
MATERIALS AND METHODS

Group division and administration
Twelve male APOE -1-mice 4 weeks ofage from Peking University were divided randomly into two groups, control and FTY720. FTY720 (from Selleck, 1.25mg/ kg/d) was administered to each male APOE-I-mouse in the FTY720 group via their drinking water beginning at 4 weeks of age. Mice were started on a high-cholesterol diet (1.25% cholesterol; Center of Guangdong Laboratory Animal, China) which was administered for 4 weeks.
Atherosclerotic lesion analysis
Atherosclerotic lesions within the thoracoabdominal aorta and aortic sinus were analyzed by transmission electron microscopy (Tecnai spirit G2, FEI, USA), Sundan IV staining for lipid deposition, and HE staining for testing atherosclerotic lesion size. Quantifications were performed by computer image analysis with the Image-Pro Plus 6.0 software.
Blood analysis
Blood samples were collected at the time of sacrifice and divided into two parts, one for measurements of differential blood cell counts using an automatic blood analyzer (Xe-2100, Sysmex, USA) and the other for cholesterol content measured by an automatic biochemical analyzer (Aeroset, Abbott, USA).
Flow cytometry analysis
Splenocytes were isolated after the final oral FTY720 administration. Fluorescent-activated cell sorter analysis was performed by FACSCalibur with the use ofCellQuest Pro software (BD Biosciences).
Cell proliferation and cytokine assays
Spleens were prepared and stimulated with 2flg/mL concanavalin A (Con A; Sigma)(l2) in vitro. Cellproliferation assay was performed by assessing CCK-8 (KeyGEN, Nanjin, China). Culture supernatants were collected and analyzed by ELISA for tumor necrosis factor-a (TNF-a), interleukin (IL)-6, IL-2, IL-lO, interferon-y (IFN-y), and TGF-~levels specific for corresponding cytokines according to the manufacturer's instructions (eBioscience).
Real-time reverse transcription polymerase chain reaction analysis
Total RNA was extracted from aortas after perfusion using TRIzol reagent (Invitrogen). Quantitative polymerase chain reaction (PCR) was performed using the One Step SYBR PrimeScript RT-PCR Kit (Takara, Shiga, Japan) and an Mx3000pTM real-time PCR system (Mx3000pTM, Stratagene, USA) according to the manufacturer's protocol. Primers were obtained from Genecopoeia. Amplification reactions were performed in duplicate and fluorescence curves were analyzed with included software.~-actin was used as an endogenous control reference. Besides, we treated the control group as control sample.
Statistical analysis
Values are expressed as mean ± SD unless indicated otherwise. Comparisons of the groups were performed by a nonparametricMann-Whitney U test. A level ofP < 0.05 was considered significant.
RESULTS
FTY720 suppresses the early development of atherosclerosis
To analyze whether treatment with oral FTY720 at the time of disease onset would protect mice from atherosclerosis development, we treated APOE -1mice with oral FTY720 every day in their drinking water while initiating a high-cholesterol diet. After 4 weeks, lipid depositions were clearly detectable within the thoracoabdominal aortas and aortic sinuses of control mice ( 
Characteristics ofApoE -1-mice after treatment
In order to explore plasma lipid profiles and differential blood cell counts in each group, we analyzed blood samples collected after different treatments. After 4 weeks on the high-cholesterol diet, differences in cholesterol and LDL cholesterol between mice in the FTY720 group and mice in the control group were statistically significant (P < 0.05, Table I) , with the exception of HD, LTG which showed no significant difference between these groups. As for body weight or blood leukocyte and lymphocyte counts, a significant difference was detected between the FTY720 group and the control group in peripheral lymphocytes, suggesting that FTY720 may have the ability to reduce peripheral lymphocytes. Moreover, data pertaining to body weight and blood leukocyte counts did not show significant differences between members of the FTY720 and control groups ( Table I) . None of the oral tolerance-treated mice died during treatment or showed unhealthy behavior.
Oral FTY720 administration strongly induced CD4+ FoxpI'Tregs and CD4+LAP+Tregs in spleens
Male Apofivmice 4 weeks of age were fed 1.25mglkg/d FTY720 in their drinking water. To investigate the effects of oral FTY720 treatment On CD4+ Foxp.I'Tregs or CD4+LAP+Treg levels in APOE-/'mice, flow cytometry studies were performed. Notably, a significant increase in CD4+Foxp3+Tregs (3.92±0.15%) was found in the CD4+T-cell population in spleens of FTY720 mice when compared with mice in the control group (l.94±0.21 %; Fig. 2A -C, P<0.05); while a significant increase in CD4+LAP+Tregs (0.51±0.14%) was found in spleens from FTY720 mice when compared with mice in the control group (0.05±0.01%; Fig.  2D -F, P < 0.05). Furthermore, previous studies on overt colitis (9) or atherosclerosis in LDLr /o mice or APOE-I-mice treated with FTY720, did not show any data suggestive of significant effects on CD4+ Foxp.J'Tregs in vivo or CD4+LAP+Tregs both in vitro or in vivo (7, 8, 15) .
FTY720 inhibited proliferation in lymphocytes from splenocytes
To determine the effect of FTY720 on the proliferation of lymphocytes, murine splenocytes were stimulated with different concentrations of FTY720 and the proliferation rate was determined by CCK8 assays. As shown in Fig. 3 , FTY720 potently stimulated proliferation of splenic cells from control group mice. Notably, the proliferation of lymphocytes was suppressed by FTY720 in a dose-dependent manner in all groups; however, at a concentration of 400pg/ml of FTY720, the differences among all groups were not significant. At concentrations of 800pg/ml and 1600pg/ml, the tendency of proliferation seemed to be even more sharply reduced.
Immune responses on cytokine production in lymphocytes after oral FTY720 treatment
To determine whether induction of various Tregs by low-dose, short-term, oral FTY720 changed the cytokine production profile from lymphocytes, cytokine secretion from spleen lymphocytes was examined in response to con A using ELISA. Consistent with previous results, significantly increased production of the anti-inflammatory cytokine TGF-~, which was the only positive cytokine in our experiments, was observed overtly in mice in the FTY720 group compared with mice from control group (259.83±19.03 vs 137.l5±4.82; P < 0.05). Lymphocytes from FTY720-treated mice secreted fewer Thl cytokines (INF-v and IL-2) and inflammation-related cytokines or chemokines (IL-6, TNF-u) following stimulation with con A than those from control mice (Fig. 4) . Type 2 helperT cells (th2) were not detected in great quantity with the exception of IL-I 0; however, no significant difference in IL-10 levels was observed between the FTY720 and control groups (137.15±4.82 vs 92.l9±7.89, P > 0.05). This result may not have been unexpected, as the role of the th2 pathway in the development of atherosclerosis remains controversial depending on the stage and/or site of the lesion, as well as on the 
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experimental model (2, 16) .
Expressions of Thl cells and CD4+LAP+Tregs and CD4+ Foxp3+Tregs mRNA markers in atherosclerotic lesions
In order to detect makers of target cells, quantitative RT-PCR was performed to test mRNA levels in thoracoabdominal tissues. Previous studies have demonstrated that T-bet is a Thl transcription factor, which would be related to the expression of Thl cells (17) and that Foxp3 is specifically expressed in Tregs (18) . Moreover, CD4+LAP+ Tregs have been shown to suppress autoimmune diseases in a TGF-f}-dependent fashion (19) (20) (21) . Thus, we analyzed T-bet, Foxp3, and TGF-~mRNA levels in thoracoabdominal tissues from APOE-1 - Greater expression of T-bet was observed in control group mice as compared with FTY720 group mice (P < 0.05, Table II ). Importantly, Foxp3 and TGF-~m RNA levels from mice in the FTY720 group were ,significantly different from levels detected in mice from the control group (Table II) atherosclerosis in this model. Importantly, we found that low-dose, short-term, oralFTY720 administration could induce expression of CD4+LAP+Tregs and CD4+ Foxp.I'Tregs, and suppress the thl response. These results were consistent with the results of the flow cytometry experiments, although those results also showed a lack of LAP or TGF-p induction following FTY720 administration.
DISCUSSION
One proposed method for reversing autoimmune diseases involves oral tolerance in order to suppress effector T cells or induce regulatory cell-driven tolerance. Oral antigens can cross from the intestine into gut-associated lymphoid tissue in two primary ways such that higher doses of antigen administration favor the induction ofanergy or deletion, whereas low doses favor the induction of active cellular regulation (3) . Interestingly, it has been shown that all major classes of Tregs including CD4+ Foxp.I" induced Tregs, CD25+Foxp3+ natural Tregs, CD4+LAP+ Tregs, and CD8+ Tregs can be induced or activated by oral (mucosal) antigen in several autoimmune diseases (22) .
Accumulating studies have demonstrated that FTY720 has beneficial effects on inhibiting atherosclerosis via inhibiting the excessive inflammatory response in mice without any adverse effects. These results may be a consequence of the ability of this compound to interfere with atherosclerosis-relevant functions of inflammatory cells including Thl cells. Additionally, the benefits of FTY720 could be accomplished via several routes of administration. For example, FTY720 was administered intravenously (0.04 mglkg per day; low dose or approximately 0.4 mg/kg per day; high dose) in LDLr /. mice for about 3 weeks (7), orally (3 mg/ kg/d) via drinking water in APOE·I'mice for 12 weeks (15) , and orally (1.25 mg/kg/d) in drinking water in APOE-/'mice for 20 weeks (8) . In all cases, FTY720 administration demonstrated beneficial effects on suppressing the early development of atherosclerosis except the study reported by Klingenberg et al., which showed that there were no changes in atherosclerotic lesions in early and established atherosclerosis after FTY720 administration (3 mg/ kg/d) in APOE-/. mice (15) . In the current study, APOE-/. mice were treated orally with FTY720 (1.25 mg/kg/d) administered in their drinking water for 4 weeks. Study results showed effects on inhibition and none of the mice died during treatment or showed unhealthy behavior. The study results implied that although FTY720 most effectively reduced atherosclerosis when administered at high doses, the atheroprotective effects of this compound were still evident when administered at low doses and over a short-term. Furthermore, experimental data showed that although LDL and cholesterol were somewhat down-regulated, FTY720 did not change HDL and total cholesterol levels in the shortterm, which suggests that its capacity to protect against atherosclerosis seems to be independent of alterations in lipid metabolism. Based on the results of the current study, it seems that oral FTY720 administration, as opposed to the usual (intravenous) route of administration, requires smaller doses over shorter periods of time.
Additionally, results of previous studies have demonstrated that FTY720 suppresses the inflammatory response and decreases levels of Thl cytokines and Th1 immunoglobulin isotypes in animals (23) . Data from the current study show the obvious down-regulation of the proinflammatory cytokines in splenocytes following short-term, low-dose treatment of mice with FTY720. Furthermore, rthe esults of the current study show that the proliferation of lymphocytes from splenocytes of different groups was suppressed by FTY720 in vitro and that survival rates became worse as the concentration ofFTY720 increased. This finding is in accordance with the results ofprevious investigations demonstrating that FTY720 induced apoptotic cell death of lymphocytes (24, 25) . Furthermore, qRT-PCR from aorta wall tissue showed decreased expression of T-bet but increased expression of Foxp3 and TGF-f3, as compared to tissue taken from control group mice. This result suggests that one of the functions of FTY720 may be to produce lymphopenia by sequestering lymphocytes from blood into lymph organs and thereby preventing their recruitment into sites of inflammation (6), or to induce some certain types of Tregs in periphery (9, 10) .
Numerous studies have been carried out in order to elucidate the relationship between FTY720 treatment and Tregs in several autoimmune diseases. Sawicka E et al. (26) reported that, when C57BL/6J mice were treated with FTY720, an increased number of CD4 + Tregs were found in spleens while CD4+CD25+T cells obtained from spleens of FTY720-pretreated donor mice contained Tregs capable of inhibiting allergen-induced airway inflammation. Furthermore, transfer of these cells resulted in a significantly more pronounced accumulation in spleens but not lymph nodes after treatment. Results from another study suggested that FTY720 could mediate the anti-inflammatory effect, at least in part, by its ability to cause the conversion of antigen-stimulated conventional T cells to Foxl'S'regulatorst l O). In a T helper type l-mediated mouse colitis model, FTY720 treatment resulted in a significant increase in FoxP3 expression in isolated CD4+T cells (9) . Sun et al. demonstrated that FTY720 induced the conversion of conventional Foxp3-CD4+T cells to Foxp.I" regulatory T cells in non-obese diabetic mice (27) . Zhou et al. concluded that FTY720 can both increase the number and enhance the function of CD4+CD2Y Tregs in vitro (28) . Regarding CD4+LAP+Tregs, recent studies have revealed that oral or nasal anti-CD3 antibody could be biologically active and induces CD4+LAP+Tregs that suppress experimental autoimmune responses, especially in encephalitis, autoimmune diabetes mellitus, lupus and atherosclerosis in a TGF-f3 -dependent fashion (12, (22) (23) (24) . However, studies never pay attention to CD4+LAP+Tregs in atherosclerosis treated by FTY720. The results from the current study confirm that FTY720 has the ability to enhance the number and function of nature CD4 + FoxP3 +T cells, and even the acquired CD However, the relationship between FTY720 action and the activity of Tregs in atherosclerosis, especially CD4+LAP+, remain to be clarified. In the present study, we show that oral FTY720 administration treatment attenuates atherosclerotic lesion formation and that this reduction is associated with an increase in the number of Tregs, including CD4 +LAP"Iregs and CD4+Foxp3+Tregs, which are possibly induced in the gut and migrate into other lymphoid organs, leading to suppression of effector T-cell immune responses. The data from the current study are the first to demonstrate a possible role for oral FTY720 treatment in inducing CD4+LAP+Tregs and CD4+Foxp3+ Tregs which may inhibit atherogenesis inAPOE-I-mice.
However, more direct evidence is needed to draw a causal relationship between the action of FTY720 and the induction of Tregs. The data generated in the current study may provide a new focus on FTY720 and its induction of CD4+LAP+Tregs, which may be helpful in defining the complex roles and interactions of the SIP (Sphingosinel-phosphate)-analog FTY720. Importantly, these data indicate that induction of Tregs in the intestine by oral FTY720 could be used as a promising preventive and therapeutic approach for atherosclerotic vascular disorders, especially during early stage of atherosclerosis. FTY720 is now used for the treatment of multiple sclerosis without any serious adverse effects. However, clinical studies on humans are required to identify the appropriate dose and efficacy of oral FTY720 in the prevention of atherosclerotic diseases. their support and help on this study. This work was supported by grants (20IOJ-EO?I) from Technology Support Project of Bureau of Finance and Bureau of Science and Information Technology of Guangzhou Municipality
